EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 2, 2022
Media advisory: The full study is linked to this news release. A visual abstract is below.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2022.0829?guestAccessKey=ffda656c-ee6b-417f-a18f-b44b745772ee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050222
Authors: Arnold R. Gammaitoni, Pharm.D., of Zogenix Inc., in Emeryville, California, is the corresponding author.
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.